2010

Selling Sickness through unbranded disease awareness campaigns?

HAI Europe Statement: EMA talks the ‘conflicts of interest’ talk, but will it walk the walk?

Systematic review of drug promotion's influence on prescribing

Doha Declaration Par 6 to be reviewed in TRIPS Council

Welfare Implications of Intellectual Property Enforcement

Dutch Minister of Health supports HAI E's financial transparency recommendations to EMA

Report exposes how Big Pharma has hijacked EU-India trade deal

In perspective: EMA comments on HAI Europe's survey of financial disclosure

Impact of HAI Europe survey results: Two weeks on

HAI Europe survey reveals new data on financial transparency of patient and consumer organisations

Open Health Forum: more room for civil society?

Priorities of the Belgian Presidency

HAI Europe recommendations for improved conflict of interest declarations at EMA

International Experts Find that Pending Anti-Counterfeiting Trade Agreement Threatens Public Interests

ISDB & MiEF criticize EMA over conflict of interest procedures

Innovation & Access at the EU High Level Event on Global Health

Review of conflict of interest policies in three European medicines regulation agencies

Quito Declaration

Independent drug bulletin and assessment reports from Spain – now in English

Quito Declaration

EU Global Health Council Conclusions presented at WHA

EU Ombudsman: Transparency rules apply to all documents held by EMA

Patient groups not only for sick people's interests – says Portuguese sociologist

Citizens call for inquiry into EU response to H1N1 outbreak

European Medicines Agency faces tough questions about patient groups' transparency

HAI hosts essay competition for students

EU-India negotiations on FTA pose a serious threat to access to affordable medicines in the developing world

Patient Groups need dose of transparency

EU lobby transparency book launch by ALTER-EU

LAC-EU Alliance for Access to Medicines welcomes compulsory license by Ecuadorian Government